Nov 2017: diagnosed with Stage IV, High-Risk Neuroblastoma; Nov 2017-April 2019: completed standard treatment protocol / no evidence of disease (NED); April 2019-April 2021: enrolled in/completed DFMO clinical trial; April 2022: RELAPSE; April 2022-June 2023: completed relapse treatment protocol / NED (again); June 2023-June 2024: enrolled in “compassionate use” high-dose DFMO clinical trial; June 2024: RELAPSE #2; July 2025 NED (again)
Monday, October 28, 2024
Monday, October 21, 2024
Monday, October 7, 2024
Saturday, October 5, 2024
Thursday, October 3, 2024
Friday, September 27, 2024
Monday, September 16, 2024
Wednesday, September 11, 2024
Friday, August 23, 2024
Monday, August 19, 2024
Friday, July 26, 2024
Monday, July 22, 2024
Friday, July 19, 2024
Thursday, July 11, 2024
Wednesday, July 3, 2024
Wednesday, June 26, 2024
Monday, March 25, 2024
Thursday, January 4, 2024
Friday, November 24, 2023
Sunday, October 1, 2023
Friday, June 30, 2023
Wednesday, June 21, 2023
Saturday, June 17, 2023